<DOC>
	<DOCNO>NCT00006005</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth gynecologic sarcoma stop blood flow tumor . PURPOSE : Phase II trial study effectiveness thalidomide treat patient recurrent persistent gynecologic sarcoma .</brief_summary>
	<brief_title>Thalidomide Treating Patients With Gynecologic Sarcomas</brief_title>
	<detailed_description>OBJECTIVES : - Determine impact survival antitumor effect thalidomide patient sarcomas carcinosarcoma ( mixed mesodermal tumor ) gynecologic origin . - Determine safety side effect profile target dose treatment regimen patient population . - Determine antiangiogenic immunologic effect treatment regimen patient . OUTLINE : Patients receive oral thalidomide daily . Treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 60 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm sarcoma carcinosarcoma ( mixed mesodermal tumor ) gynecologic origin amenable resection radiotherapy Measurable disease Lesions accurately measure least 1 dimension least 20 mm long diameter conventional technique least 10 mm helical CT scan Histologically cytologically confirm neoplastic nature solitary lesion No nonmeasurable disease , define : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Unconfirmed abdominal mass follow image technique Cystic lesion Documented recurrence persistence follow appropriate surgery , radiotherapy , and/or chemotherapy Postmenopausal status post hysterectomy PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,000/mm^3 Platelet count least 50,000/mm^3 Hepatic : Bilirubin normal Transaminases le 2.5 time upper limit normal Renal : Creatinine le 1.5 mg/dL Other : No grade 2 great peripheral neuropathy No medical social factor would preclude study , include inability take oral medication No serious illness require immediate therapy Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week since mitomycin nitrosoureas ) Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics Other : At least 30 day since prior noncytotoxic experimental antiemetic antifungal investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>stage I uterine sarcoma</keyword>
	<keyword>stage II uterine sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>uterine carcinosarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
	<keyword>endometrial stromal sarcoma</keyword>
</DOC>